Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Clinical Study of Tolerability, Safety and Pharmacokinetics of QHRD106 Injection in Chinese Healthy Subjects With Single Doses

NCT06388772 is registered in ClinicalTrials.gov with Changzhou Qianhong Bio-pharma Co., Ltd. as lead sponsor.

NCT NCT06388772
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06388772 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Clinical Study of Tolerability, Safety and Pharmacokinetics of QHRD106 Injection in Chinese Healthy Subjects With Single Doses
Lead sponsor
Changzhou Qianhong Bio-pharma Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
July 5, 2021
Completion date
January 6, 2023
Enrollment
74 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute ischemic stroke